Mt. Vernon Register-News

Top News

July 1, 2013

Fish-oil pills lure drugmakers though benefits remain unproven

Fish oil has been touted as useful for everything from growing hair to treating clinical depression. Now drug makers are stepping up their promotion of its benefits for treating heart disease.

AstraZeneca, Amarin and GlaxoSmithKline are betting the market for prescription fish-oil pills will follow the success of cholesterol-lowering drugs including Lipitor, once the world's best-selling medicine with revenue of $13 billion a year.

Heart disease remains the world's biggest killer, accounting for 30 percent of global deaths, even as statins and other treatments have become more widely used. Now that Lipitor and many other statins have cheaper, generic competitors, drugmakers are looking for new ways to tackle the array of conditions that can lead to heart disease, including coupling triglyceride treatments with existing cholesterol-lowering pills for a one-two punch.

 "The number of people with elevated triglyceride levels is rising rapidly across the world, due in part to the increasing prevalence of obesity and diabetes," AstraZeneca Chief Executive Officer Pascal Soriot said when he bought fish-oil pill maker Omthera Pharmaceuticals Inc. for $443 million last month. "There is a clear need for effective and convenient alternatives to some of the existing treatments."

Unlike capsules that can be bought in health-food stores, the drugmakers' products are available only with a prescription, are highly concentrated and undergo a several-step purification process approved by the U.S. Food and Drug Administration.

There's a hitch, however. Statins have been proven in studies to cut heart risk. The benefits of fish-oil pills are less certain. Though they target triglycerides, fatty substances in the blood that have been linked to a higher risk of heart attacks, little evidence exists that the pills prevent heart attacks.

"It's very unclear what role fatty acids play for cardiac patients," Mark Urman, a member of the American College of Cardiology Prevention Committee and practicing cardiologist at Cedars-Sinai Heart Institute, said in an interview. "The lab tests look better, but has it done the patient any good?"

Study results have been mixed. Japanese research on almost 19,000 people who took fish oil with a statin had a 19 percent lower risk of heart attacks, sudden cardiac death and other major coronary events, compared with those who took a statin alone.

A late-stage trial of Vascepa sponsored by Amarin found that it cut triglyceride levels by almost 22 percent at a 4-gram dose and 10 percent at a 2-gram dose without raising cholesterol levels in patients taking statins.

Other trials have shown little or no benefit. A study of more than 12,500 patients showed that a 1-gram daily dose of omega-3 fatty acids didn't prevent death or other cardiovascular events compared with placebo, according to an article in the New England Journal of Medicine in June 2012. And a review of data from 68,000 patients who took fish oil supplements over 24 years showed no reduction in risk of heart attack, stroke and death, the Journal of the American Medical Association said in September.

If cleared by regulators, AstraZeneca's Epanova would be the latest prescription pill to enter the market. It would bolster the London-based company's best-selling drug, a statin called Crestor, once it faces generic competition in 2016. While the drugmaker is still formulating its strategy, the Crestor sales team will pitch the product as an added benefit to the statin, said William Mongan, AstraZeneca's executive director of U.S. business development.

Amarin won U.S. approval to market Vascepa to people who have triglyceride levels of 500 milligrams per deciliter of blood or greater, a group of about 4 million people, according to the Dublin-based drugmaker. It's also seeking clearance to sell Vascepa for an additional 40 million people who have triglyceride levels between 200 milligrams and 500 milligrams, a "multi-billion dollar market opportunity."

Glaxo, whose Lovaza has brought in almost 2.5 billion pounds ($3.8 billion) in sales in the past five years, is more guarded about the market's prospects. In its 2012 annual report, the London-based drugmaker said the market had declined by 7 percent compared with 2011. Economic pressures have resulted in fewer doctor visits and reduced testing for conditions such as very high triglycerides that don't have any obvious symptoms, Glaxo said.

Without much evidence to support the claim that the pills cut heart risk, health-care purchasers remain skeptical of the benefits. Britain's medical spending watchdog, the National Institute for Health and Care Excellence, this month said it no longer recommends that heart attack survivors take fish-oil pills to prevent further heart attacks, citing their "minimal" benefit.

"It should be clear that they are not alternatives to statins," Cedars-Sinai's Urman said. He prescribes them predominately for patients who are in danger of developing pancreatitis, a painful inflammation of the pancreas caused by elevated triglyceride levels.

Vascepa has a long way to go to catch Lovaza. The drug had $4.3 million in sales between January and the end of April compared with $424.6 million for Lovaza, according to Symphony Health, a U.S. consulting firm. Amarin had to hire its own sales force after failing to find either a buyer for the company or a partner to help market Vascepa.

Amarin has fallen 60 percent in the last year and closed yesterday at $5.68, giving the drugmaker a market value of $854 million.

Analysts predict Lovaza sales will decline about 1.4 percent this year, according to the average of eight estimates compiled by Bloomberg.

"Do we need more preparations on the market? No," said Robert Eckel, director of the lipid clinic at the University of Colorado Hospital at the Anschutz Medical Campus in Aurora, Colo., and past president of the American Heart Association. "Do we have all of the answers about whether they are beneficial or not? No, we don't have those yet."

 

1
Text Only
Top News
  • Smartphone kill switches are coming

    Smartphones need kill switches. It's a relatively easy solution to the pricey (and irritating) problem of smartphone theft. But who would have thought that the big carriers would team up with Apple, Google, Microsoft, Nokia, Samsung and lots of other manufacturers to voluntarily begin adding the technology by July 2015? The cooperative spirit! It makes so much sense!

    April 18, 2014

  • VIDEO: Boston bomb scare defendant appears in court

    The man accused of carrying a backpack containing a rice cooker near the Boston Marathon finish line on the anniversary of the bombings was arraigned Wednesday. He's being held on $100,000 bail.

    April 17, 2014

  • Doctors to rate cost effectiveness of expensive cancer drugs

    The world's largest organization of cancer doctors plans to rate the cost effectiveness of expensive oncology drugs, and will urge physicians to use the ratings to discuss the costs with their patients.

    April 16, 2014

  • bomb1 VIDEO: A year after marathon bombing, Boston remains strong

    The City of Boston came together Tuesday to honor those who were injured and lost their lives at the Boston Marathon on the one-year anniversary of the bombing. While the day was sure to be emotional, those affected by last year's race are showing they won't let the tragedy keep them down.

    April 15, 2014 1 Photo

  • Search teams will send unmanned sub to look for missing Malaysian airliner

    Teams searching for a missing Malaysian airliner are planning for the first time to send an unmanned submarine into the depths of the Indian Ocean to look for wreckage, an Australian official leading the multi-nation search said Monday.

    April 14, 2014

  • 25801486.jpg VIDEO: Northern California bus crash kills 10

    At least nine people died in Northern California on Thursday night, in an accident involving a bus, a car and FedEx truck. The bus was filled with high school students from Southern California who were on their way to visit a college campus.

    April 11, 2014 1 Photo

  • VIDEO: CBS taps Colbert as Letterman’s Late Show successor

    Bloomberg’s Jon Erlichman reports that CBS has announced Stephen Colbert as its choice to replace the retiring David Letterman as host of “The Late Show” on Bloomberg Television’s “Lunch Money.”

     

    April 10, 2014

  • Teen stabs 20 at Pittsburgh-area high school

    MURRYSVILLE, Pa. (AP) — Flailing away with two knives, a 16-year-old boy with a "blank expression" stabbed and slashed 19 students and a police officer in the crowded halls of his suburban Pittsburgh high school Wednesday before an assistant principal tackled him.

    April 9, 2014

  • Fast, cheap test can help save lives of many babies

    As Easley did more research into her daughter's death, she learned that a pilot program had started just months earlier at Holy Cross Hospital in Silver Spring, Md. (Easley had delivered at a different hospital in the Washington area.) The program's goal was to screen every newborn with a simple pulse oximeter test that can help detect heart problems such as Veronica's, allowing doctors to respond.

    April 8, 2014

  • 297px-Starbucks_Corporation_Logo_2011.svg.png Why Starbucks won't recycle your paper coffee cup

    When you drop that used white paper cup into the bin next to the door at a Starbucks, have you done your part to save the planet? Starbucks has long hoped that you would think so. After all, there's no better way to attract an affluent, eco-conscious clientele than to convince customers that your disposable product is "renewable."

    April 7, 2014 1 Photo